No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study

BackgroundTNF- plays a role in angiogenesis and collagen synthesis, both essential in the wound healing process. There are concerns that pre-operative anti-TNF- treatment may influence the surgical stress response and increase the risk of surgical complications. The aim of this study was to describe the surgical stress response in patients with inflammatory bowel disease (IBD) and to investigate whether the pre-operative administration of anti-tumor necrosis factor alpha (anti-TNF-) agents modify the surgical stress response.MethodsThis was a prospective, multi-center cohort pilot study. The primary outcome was the change in concentration of immunological biomarkers of the surgical stress response (TNF-, IL-6, and IL-10). Secondary outcome measures were changes in IL-8, IL-17A, C-reactive protein, white blood cells, cortisol, transferrin, ferritin, and D-Dimer in addition to 30days' post-operative complications and length of post-operative stay in the hospital (LOS).ResultsForty-six patients with IBD undergoing major abdominal surgery were included, and 18 received anti-TNF- treatment pre-operatively. Peak increase of most of the immunological biomarkers occurred 6 hours after surgical incision. Then the concentration decreased after 24h followed by a plateau at 48h. After adjusting for confounders including detectable blood concentrations, no difference in the concentrations of immunological, endocrinological or haematological biomarkers of stress was found between anti-TNF- treated and anti-TNF- naive patients. No increase in post-operative complications or LOS was noticed in patients who received anti-TNF- treatment.ConclusionsAnti-TNF- did not affect surgical stress response in this pilot study. Withdrawal of anti-TNF- drugs prior to surgical intervention in IBD patients might not be justified without measurement of drug concentration and drug antibodies.Trial registrationClinicaltrails.gov.: NCT01974869.